Perspective Therapeutics, Inc.CATXNYSE

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 82% recommend buying.

Consensus Rating

Buy

11 analysts·Moderate coverage

82%

Rating Distribution

Strong Buy

00%

Buy

982%

Hold

218%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 112% higher.

Bear Case

$7.00

+35%

Consensus

$11.00

+112%

Bull Case

$14.00

+169%

Price Range11 analysts

Low

Consensus

High

$7.00

$14.00

Current Target

Current Price

$5.20

Upside to Target

$5.80

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.34(9 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-15.31%

EPS—

FY2028

Rev+2919.30%

EPS—

FY2029

Rev+1249.31%

EPS—

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-1.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 30, 2026H.C. Wainwright

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

Target:$12.00

+181.7%from $4.26

Nov 21, 2025UBS

Perspective Therapeutics price target lowered to $7 from $18 at UBS

Target:$7.00

+230.2%from $2.12

Oct 10, 2025BTIG

Perspective Therapeutics initiated with a Buy at BTIG

Target:$14.00

+233.3%from $4.20

Oct 24, 2024UBS

UBS Starts Perspective Therapeutics Inc (CATX) at Buy

Target:$20.00

+71.1%from $11.69

Oct 14, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

Target:$22.00

+73.8%from $12.66

Sep 25, 2024Truist Financial

Truist Securities Starts Perspective Therapeutics Inc (CATX) at Buy

Target:$21.00

+71.0%from $12.28

Jul 25, 2024Bank of America Securities

Perspective Therapeutics initiated with a Buy at BofA

Target:$24.00

+87.2%from $12.82

Jun 18, 2024Oppenheimer

Perspective Therapeutics Inc (CATX) PT Raised to $19 at Oppenheimer

Target:$19.00

+59.3%from $11.93

Jun 14, 2024RBC Capital

RBC Capital Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX)

Target:$3.00

+161.2%from $1.15

May 15, 2024Oppenheimer

Perspective Therapeutics Inc (CATX) PT Raised to $2 at Oppenheimer

Target:$2.00

+27.4%from $1.57

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance